Prosecution Insights
Last updated: April 19, 2026

Janux Therapeutics Inc.

7 pending office actions

Portfolio Summary

7
Total Pending OAs
1
Final Rejections
6
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18256278 PEPTIDE COMPOSITIONS AND METHODS FOR ANTI-CD3 BINDING DOMAINS YAO, LEI 1642 Non-Final OA Jun 07, 2023
18256276 HALF-LIFE EXTENDING COMPOSITIONS AND METHODS SAOUD, CHRISTINE J 1645 Non-Final OA Jun 07, 2023
18314077 COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS CUNNINGCHEN, KATHLEEN MARY 1646 Non-Final OA May 08, 2023
18249886 MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF TAYLOR, LIA ELAN 1641 Non-Final OA Apr 20, 2023
18031724 ANTIBODIES TARGETING PSMA AND CD3 AND USES THEREOF JUEDES, AMY E 1644 Final Rejection Apr 13, 2023
18063419 MODIFIED ANTIBODIES CANELLA, KAREN A 1643 Non-Final OA Dec 08, 2022
17616281 COMPOSITIONS AND METHODS RELATING TO TUMOR ACTIVATED T CELL ENGAGERS LUNDE, GRACE HENRY 1641 Non-Final OA Dec 03, 2021

Managing Janux Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month